This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Optimising Treatment With Tumour Necrosis Factor I...
Clinical trial

Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A �Proof Of Principle� And Exploratory Trial. (OPTTIRA)

Read time: 1 mins
Last updated:17th Aug 2010
The study investigates whether in it is possible to reduce the dose of or even stop TNF-inhibitors without adversely affecting the control of this disease. This will be assessed by looking at: a. The risk of disease flares (using the disease activity score with a 28 tender and swollen joint count (DAS28). An increase of disease activity score (DAS28) of 0.6 or more represents adversely affecting disease control and is considered a flare) b. If flares are reversed by reverting to the original TNF inhibitor dosage c. If either tapering group show worse key RA assessments including disease activity (DAS28) and disability as measured by health assessment questionnaire (HAQ) scores d. Structural damage (plain hand and feet)
Category Value
Study start date 2010-08-17

View full details